
Dialysis firm DaVita's DVA.N shares rise 10.6% to $121.05 premarket after co forecasts annual profit above estimates
Co expects 2026 adj. EPS to be between $13.60 and $15 vs analysts' average estimate of $12.65 - LSEG data
DVA attributes upbeat estimate to steady demand for its kidney dialysis services
Barclays raises PT to $158 from $143, an upside of 42% to DVA's last close of $111.19
Co expects headwind of $40 mln in 2026, $70 mln in 2027 with the expiration of the Affordable Care Act subsidy, but will be offset by elimination of $45 mln cyber-incident impact in 2025, says chief financial officer Joel Ackerman
Co reports Q4 adj. EPS of $3.4 vs analysts' estimate of $3.16 - LSEG data
Q4 profit lifted by higher reimbursement rates and a slight improvement in the mix and seasonal impact of flu vaccines, says co
DVA stock dropped 24% in 2025